KR20180070563A - 통증 치료용 조성물 및 방법 - Google Patents

통증 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20180070563A
KR20180070563A KR1020187008538A KR20187008538A KR20180070563A KR 20180070563 A KR20180070563 A KR 20180070563A KR 1020187008538 A KR1020187008538 A KR 1020187008538A KR 20187008538 A KR20187008538 A KR 20187008538A KR 20180070563 A KR20180070563 A KR 20180070563A
Authority
KR
South Korea
Prior art keywords
fusion protein
toxin
receptor
pain
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187008538A
Other languages
English (en)
Korean (ko)
Inventor
알. 존 콜리어
이삭 치우
브레들리 엘. 펜텔트
케이스 앨런 포스터
실파 팔런
사이 만 리우
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
메사추세츠 인스티튜트 오브 테크놀로지
입센 파마 에스.에이.에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지, 메사추세츠 인스티튜트 오브 테크놀로지, 입센 파마 에스.에이.에스 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Publication of KR20180070563A publication Critical patent/KR20180070563A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187008538A 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법 Withdrawn KR20180070563A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562210610P 2015-08-27 2015-08-27
US62/210,610 2015-08-27
PCT/US2016/049106 WO2017035508A1 (en) 2015-08-27 2016-08-26 Compositions and methods for treatment of pain

Publications (1)

Publication Number Publication Date
KR20180070563A true KR20180070563A (ko) 2018-06-26

Family

ID=58101095

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187008538A Withdrawn KR20180070563A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법
KR1020187008537A Withdrawn KR20180050679A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187008537A Withdrawn KR20180050679A (ko) 2015-08-27 2016-08-26 통증 치료용 조성물 및 방법

Country Status (11)

Country Link
US (4) US10704035B2 (enExample)
EP (2) EP3341392A4 (enExample)
JP (2) JP2018530315A (enExample)
KR (2) KR20180070563A (enExample)
CN (2) CN108602861A (enExample)
AU (2) AU2016310521A1 (enExample)
BR (2) BR112018003794A2 (enExample)
CA (2) CA2994560A1 (enExample)
EA (1) EA201890587A1 (enExample)
MX (1) MX2018002183A (enExample)
WO (2) WO2017035507A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080682A1 (ko) * 2022-10-12 2024-04-18 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220354962A1 (en) * 2015-05-12 2022-11-10 The Trustees Of The University Of Pennsylvania Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
AU2016310521A1 (en) 2015-08-27 2018-03-01 Massachusetts Institute Of Technology Compositions and methods for treatment of pain
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
US12098169B2 (en) * 2017-09-29 2024-09-24 Children's Medical Center Corporation Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof
UA128185C2 (uk) 2018-01-29 2024-05-01 Іпсен Біофарм Лімітед Ботулінічний нейротоксин, який розщеплює ненейронний snare
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CA3101481A1 (en) * 2018-05-30 2019-12-05 The Governing Council Of The University Of Toronto Methods and kits for identifying a protein associated with receptor-ligand interactions
US20210380700A1 (en) * 2018-07-06 2021-12-09 Abmax Biopharmaceuticals De-adcc/cdc functions of antibodies and their applications
SG11202100646SA (en) * 2018-07-31 2021-02-25 Snoretox Pty Ltd Pegylated tetanus neurotoxins and treatment of hypotonia
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
WO2021150581A2 (en) * 2020-01-21 2021-07-29 Trustees Of Dartmouth College Immunologically optimized botulinum toxin light chain variants
WO2021156890A2 (en) * 2020-02-03 2021-08-12 Premas Biotech Private Limited Recombinant expression platform, constructs and methods for expression of difficult to express proteins (dte-ps)
US20230165812A1 (en) * 2020-02-27 2023-06-01 President And Fellows Of Harvard College Nociceptor neurons control cancer immunosurveillance

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
CA2239909A1 (en) 1995-12-13 1997-07-03 President And Fellows Of Harvard College Use of toxin peptides and/or affinity handles for the delivering compounds into cells
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6767896B1 (en) 1999-01-29 2004-07-27 Cognetix, Inc. Conotoxin peptides
CA2380457A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
ES2233495T3 (es) * 1999-09-24 2005-06-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Proteinas antigenicas protectoras contra toxinas de antrax mutadas que se dirigen especificamente a celulas que contienen altas cantidades de metaloproteinasas de la superficie celular o receptores del activador de plasminogeno.
AU2740401A (en) 1999-12-30 2001-07-16 Cognetix, Inc. O-superfamily conotoxin peptides
US20040033585A1 (en) * 2002-06-07 2004-02-19 Mccormick Alison A. Flexible vaccine assembly and vaccine delivery platform
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
JP2009514545A (ja) 2005-11-08 2009-04-09 アテリス ラボラトリーズ μ−コノトキシンぺプチドおよびμ−コノトキシンぺプチドの局所麻酔薬としての使用
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
WO2008008803A2 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US9284358B2 (en) 2006-07-18 2016-03-15 University Of Utah Research Foundation Conotoxin peptides
CA2824154A1 (en) 2011-01-10 2012-07-19 President And Fellows Of Harvard College Method for delivering agents into cells using bacterial toxins
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
AU2013222334A1 (en) * 2012-02-23 2014-09-11 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
WO2013177231A1 (en) 2012-05-21 2013-11-28 Massachusetts Institute Of Technology Translocation of non-natural chemical entities through anthrax protective antigen pore
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014088928A1 (en) 2012-12-03 2014-06-12 President And Fellows Of Harvard College Methods for making targeted protein toxins by sortase-mediated protein ligation
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
AU2016310521A1 (en) 2015-08-27 2018-03-01 Massachusetts Institute Of Technology Compositions and methods for treatment of pain

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024080682A1 (ko) * 2022-10-12 2024-04-18 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체
KR102728382B1 (ko) * 2022-10-12 2024-11-14 주식회사 알케미어 보툴리눔 독소의 경쇄 변이체

Also Published As

Publication number Publication date
EP3341392A1 (en) 2018-07-04
US11104892B2 (en) 2021-08-31
KR20180050679A (ko) 2018-05-15
US11753633B2 (en) 2023-09-12
AU2016310521A1 (en) 2018-03-01
MX2018002183A (es) 2018-05-28
CN108350039A (zh) 2018-07-31
CA2994560A1 (en) 2017-03-02
EP3341391A1 (en) 2018-07-04
EP3341391A4 (en) 2019-03-06
US20180244731A1 (en) 2018-08-30
US20180251740A1 (en) 2018-09-06
US20200362325A1 (en) 2020-11-19
WO2017035507A1 (en) 2017-03-02
BR112018003794A2 (pt) 2018-09-25
BR112018003782A2 (pt) 2018-09-25
EA201890587A1 (ru) 2018-09-28
AU2016312685A1 (en) 2018-03-01
JP2018525021A (ja) 2018-09-06
JP2018530315A (ja) 2018-10-18
WO2017035508A1 (en) 2017-03-02
US20220033795A1 (en) 2022-02-03
CN108602861A (zh) 2018-09-28
CA2994729A1 (en) 2017-03-02
EP3341392A4 (en) 2019-01-23
US10704035B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
US11104892B2 (en) Compositions and methods for treatment of pain
TWI725963B (zh) 工程化之肉毒桿菌神經毒素
KR102617830B1 (ko) 양이온성 신경독소
US7514088B2 (en) Multivalent Clostridial toxin derivatives and methods of their use
US20240018196A1 (en) Topical compositions and uses
US20200255481A1 (en) Neurotoxin-like toxin and uses thereof
JP7100020B2 (ja) 操作されたボツリヌス神経毒素
TW201639876A (zh) 嵌合多肽
CA3228712A1 (en) Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
US20180298367A1 (en) Suppression of itch
US20240158773A1 (en) Engineered botulinum neurotoxin a protease domain with improved efficacy
HK1261168A1 (en) Compositions and methods for treatment of pain
US20240216487A1 (en) Intramuscular compositions of botulinum neurotoxins

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000